GLUMETZA Drug Patent Profile

Which patents cover Glumetza, and when can generic versions of Glumetza launch?

Glumetza is a drug marketed by Santarus Inc and is included in one NDA.

The generic ingredient in GLUMETZA is metformin hydrochloride. There are forty-nine drug master file entries for this compound. Eighty-one suppliers are listed for this compound. Additional details are available on the metformin hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Glumetza

A generic version of GLUMETZA was approved as metformin hydrochloride by CHARTWELL on January 24^th, 2002.

Summary for GLUMETZA

US Patents:	0
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for GLUMETZA

Paragraph IV (Patent) Challenges for GLUMETZA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
GLUMETZA	Extended-release Tablets	metformin hydrochloride	500 mg and 1000 mg	021748	1	2009-07-27

US Patents and Regulatory Information for GLUMETZA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Santarus Inc	GLUMETZA	metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021748-002	Jun 3, 2005		DISCN	Yes	No
Santarus Inc	GLUMETZA	metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021748-001	Jun 3, 2005		DISCN	Yes	No

International Patents for GLUMETZA

See the table below for patents covering GLUMETZA around the world.

Country	Patent Number	Title	Estimated Expiration
Denmark	1476138
Japan	2003535886
World Intellectual Property Organization (WIPO)	03072025
Australia	8138698
South Korea	20030023876
Canada	2476496	FORMES POSOLOGIQUES A LIBERATION CONTROLEE (CONTROLLED RELEASE DOSAGE FORMS)
Austria	256455

Supplementary Protection Certificates for GLUMETZA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1506211	C 2014 029	Romania		PRODUCT NAME: COMBINATIE DE DAPAGLIFLOZIN SAU O SARE ACCEPTABILAFARMACEUTIC A ACESTUIA SI METFORMINA SAU O SARE ACCEPTABILA FARMACEUTIC A ACESTEIA; NATIONAL AUTHORISATION NUMBER: EU/1/13/900; DATE OF NATIONAL AUTHORISATION: 20140116; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/13/900; DATE OF FIRST AUTHORISATION IN EEA: 20140116
1412357	PA2008013	Lithuania		PRODUCT NAME: SITAGLIPTINUM PHOSPHAS MONOHYDRICUS, METFORMINI HYDROCHLORIDUM; REG. NO/DATE: EU/1/08/455/001-014 20080716
1532149	132013902118390	Italy		PRODUCT NAME: LINAGLIPTIN + METFORMINA CLORIDRATO(JENTADUETO); AUTHORISATION NUMBER(S) AND DATE(S): DA EU/1/12/780/001 A EU/1/12/780/027, 20120720
1261586	12C0028	France		PRODUCT NAME: ASSOCIATION COMPRENANT LA SAXAGLIPTINE OU UN DE SES SELS ET LA METFORMINE OU UN DE SES SELS, Y COMPRIS L'ASSOCIATION CHLORHYDRATE DE SAXAGLIPTINE ET CHLORHYDRATE DE METFORMINE; REGISTRATION NO/DATE: EU/1/11/731/001 20111124
2498758	2020C/509	Belgium		PRODUCT NAME: QTRILMET - METFORMINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI; SAXAGLIPTINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI; DAPAGLIFLOZINE OU UN SOLVATE PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI; AUTHORISATION NUMBER AND DATE: EU/1/19/1401 20191113
1506211	PA2014026,C1506211	Lithuania		PRODUCT NAME: DAPAGLIFLOZINUM + METFORMINUM; REGISTRATION NO/DATE: EU/1/13/900 20140116
1261586	2012C/016	Belgium		PRODUCT NAME: UNE COMBINAISON DE PRODUITS DE SAXAGLIPTINE ET DE METFORMINE AINSI QUE TOUT SELS PHARMACEUTIQUEMENT ACCEPTABLES, DONT LES SELS DE CHLORHYDRATE DE SAXAGLIPTINE ET DE METFORMINE; AUTHORISATION NUMBER AND DATE: EU/1/11/731/001 20111128

Investment Scenario, Market Dynamics, and Financial Trajectory for GLUMETZA

Last updated: February 3, 2026

Summary

GLUMETZA (metformin hydrochloride extended-release) is a prescription medication primarily used to manage type 2 diabetes mellitus. Given its established efficacy and favorable safety profile, GLUMETZA's market position depends on evolving diabetes treatment algorithms, patent status, competitive landscape, and regulatory environment. This report analyzes current market dynamics, forecasted financial prospects, investment risks, and growth opportunities linked to GLUMETZA, providing a comprehensive framework for decision-makers.

---

What Is the Current Market Landscape for GLUMETZA?

Product Overview and Therapeutic Position

Product Name	Active Ingredient	Formulation	Approval Date	Indication	Market Share (2023)
GLUMETZA	Metformin Hydrochloride Extended-Release	500 mg, 1000 mg tablets	2004 (FDA)	Type 2 Diabetes Mellitus	Approximately 5-8% (US estimates)

Key Attributes:

• Demonstrates improved gastrointestinal tolerability over immediate-release formulations.
• Long-standing generic and branded competition.
• Patent expiry: The original patent expired in 2016; however, formulation-specific patents and exclusivities extend market protection in some regions.

Regulatory and Patent Landscape

• Patent Status: Patent-related exclusivity for formulation expired in 2016. Nonetheless, certain formulation patents or patent extensions could delay generic entry in specific jurisdictions (US, EU).
• Regulatory Environment: Equivalence to other metformin products approved broadly; regulatory barriers are minimal post-patent expiry.
• Pricing and Reimbursement: The shift toward generics has reduced prices; reimbursement policies influence prescription patterns.

Historical Sales Data & Revenue

Year	Estimated US Sales (USD millions)	Global Market Share (Estimate)
2018	200	4%
2019	180	3.8%
2020	150	3.7%
2021	130	3.5%
2022	110	3.2%

Declining sales due to generic competition, with minor shifts toward alternative therapies such as SGLT2 inhibitors and GLP-1 receptor agonists.

---

Market Dynamics Impacting GLUMETZA

Demand Drivers

• Prevalence of Type 2 Diabetes: Globally rising—estimated 537 million adults affected in 2021 (IDF). Compound annual growth rate (CAGR) of global diabetic population ~2.4% (2021–2027).
• Healthcare Guidelines: Glucose-lowering strategies favor metformin as first-line treatment; expected to maintain steady demand.
• Formulation Preference: Extended-release formulations preferred for gastrointestinal tolerability; niche for GLUMETZA among monotherapy candidates.

Competitive Landscape

Key Competitors	Formulations	Market Share (%)	Notable Features
Glucophage (immediate-release)	Immediate-release	~60% globally	Widely prescribed, lower cost
Metformin XR (generic)	Extended-release	~25%	Cost-effective alternative
Other branded XR products	XR formulations	~10%	Slightly differentiated formulations
Non-metformin options	SGLT2 inhibitors, GLP-1 agents	~5%	For advanced or resistant cases

• Price Competition: Generics have significantly diminished the revenue potential for GLUMETZA branded sales.
• Prescribing Trends: Increase in use of newer classes in certain markets might marginalize metformin but remains the foundational therapy.

Regulatory and Policy Developments

• Pricing Controls: Implemented in multiple regions to curb drug costs, affecting margins.
• Patent Challenges and Litigation: Ongoing legal disputes over formulation patents may influence timing for generic competition.

---

Financial Trajectory and Investment Outlook

Forecasted Revenue Trends (2023–2030)

Year	Projected US Sales (USD millions)	Annual Growth Rate (%)	Reasoning
2023	100	-10%	Market erosion, generic entry
2024	85	-15%	Increased generics competition
2025	70	-20%	Penetration of alternative therapies
2026	60	-14%	Market stabilization, niche adoption
2027	50	-17%	Shift to new therapies
2030	40–45	Continued decline	Marginalized use, patent barriers

Note: The projections reflect decline due to intense commoditization, with some residual demand among specific patient segments.

Key Investment Risks and Opportunities

Risks	Mitigation Strategies	Opportunities
Patent expiry leading to generic competition	Diversify portfolio, innovation	Development of combination formulations or fixed-dose combos
Market shift toward newer therapies	Expand indication claims, increase awareness	Collaborate on clinical trials demonstrating benefits in specific subpopulations
Price pressure from payers	Price optimization, value-based contracting	Focus on niche markets with unmet needs
Regulatory changes	Active compliance, proactive engagement	Leverage regulatory pathways for formulations with enhanced features

Potential Growth Opportunities

• Formulation Innovation: Extended-release formulations with improved pharmacokinetics.
• New Indications: Adjunct in polycystic ovary syndrome (off-label use) and prediabetes.
• Geographic Expansion: Emerging markets with rising diabetes prevalence.

---

Comparison with Key Market Players

Parameter	GLUMETZA	Glucophage (generic)	Jardiance (empagliflozin)	Victoza (liraglutide)
Launch Year	2004	1994	2014	2010
Market Share (US, 2023)	3.2–8%	Dominant	Growing	Niche but expanding
Revenue (USD millions, 2022)	110	Billions (generics)	3,500+	4,500+
Regulatory Status	FDA-approved	Multiple generics	Approved for multiple indications	Approved, including weight management

Deep Dive: Patent and Regulatory Impact

Aspect	Details	Implication
Patent Expiry	2016 for key formulation patents	Entry of generics in US post-2016
Patent Extensions	Possible in certain regions	Temporary market exclusivity
Regulatory Approvals	Broad globally	Ease of market entry for competitors
Regulatory Barriers	Minimal in established markets	Increased competition

---

FAQs

1. How does patent expiry impact GLUMETZA’s market?
Patent expiry generally leads to the entry of generics, significantly reducing branded sales. After the 2016 patent expiration, competition increased, leading to a sales decline.

2. What are the main drivers for continued demand for GLUMETZA?
Persistent reliance on metformin as first-line therapy, patient preference for extended-release formulations with better tolerability, and limited efficacy of some generics can maintain niche demand.

3. How does the competitive environment affect investment in GLUMETZA?
Intense price competition and the rise of newer therapeutic classes pose risks. However, opportunities exist in formulation innovation and niche markets to sustain revenue streams.

4. What regulatory strategies could prolong GLUMETZA’s market presence?
Filing for new formulations, obtaining additional indications, and leveraging orphan or unserved patient populations can extend patent protection and market relevance.

5. Which markets offer the most growth potential for GLUMETZA?
Emerging markets with rising diabetes prevalence and limited access to newer therapies present significant opportunities for niche sales.

---

Key Takeaways

• Market Decline: Sales are decreasing due to generic competition and shift towards newer antidiabetic agents.
• Growth Opportunities: Innovation in formulations, new indications, and geographic expansion can mitigate decline.
• Investment Risks: Patent expiration, intense price competition, and evolving treatment guidelines underscore the need for strategic adaptability.
• Long-term Outlook: Limited growth prospects in mature markets; focus on niche segments and formulation improvements for sustainable revenue.

---

References

[1] International Diabetes Federation. "IDF Diabetes Atlas," 2021.
[2] FDA Patent and Exclusivity Data, 2016–2022.
[3] IQVIA, "Pharmaceutical Market Data," 2022.
[4] Market Research Future. "Global Anti-Diabetics Market Analysis," 2022.
[5] Centers for Medicare & Medicaid Services. "Drug Pricing and Reimbursements," 2023.